Relapsed/refractory acute myeloid leukemia (AML) - Pipeline Insight, 2024

This “Relapsed/refractory acute myeloid leukemia (AML)- Pipeline Insight, 2024” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Relapsed/refractory acute myeloid leukemia (AML) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Relapsed/refractory acute myeloid leukemia (AML): Understanding

Relapsed/refractory acute myeloid leukemia (AML): Overview

Relapsed/refractory acute myeloid leukemia (AML) is a devastating disease with a poor prognosis and represents a major unmet medical need. The prognosis of relapsed acute myeloid leukemia (AML) is poor and treatment is challenging. The signs and symptoms of acute myeloid leukemia (AML) are common to other, less serious illnesses. It is common for people with AML to feel a loss of well-being because of the underproduction of normal bone marrow cells. Symptoms of a low red blood cell count (called “anemia”) include: Fatigue, weakness, shortness of breath during normal physical activities, lightheadedness, dizziness or faintness, headaches and pale complexion. Other general symptoms of AML include: Loss of appetite, unexplained weight loss, discomfort in bones or joints, fullness or swelling in the abdomen, due to an enlarged spleen or liver. While the most potent treatment modality for patients who achieve a complete remission after relapse is still allogeneic haematopoietic cell transplantation (allo-HCT), both transplant-related mortality and relapse rates are high and many patients are not candidates for this approach. After a few decades of relative stasis in this field, a large number of novel approaches have become available to tackle this highly fatal disease. While cure of relapsed/refractory AML without allo-HCT is currently unlikely, treatments are becoming less toxic and remissions are lasting longer. The management of acute myeloid leukaemia (AML) relapse in adults continues to remain a major therapeutic challenge despite the increasing availability of novel agents including targeted therapies. When considering treatment options for patients with relapsed/refractory AML, patient- and disease-related factors [e.g., age, comorbidities, performance status, cytogenetic and molecular abnormalities, prior lines of chemotherapy, history of prior allogeneic haematopoietic cell transplant (allo-HCT), and time to relapse after previous complete remission (CR)] should be carefully evaluated.

Relapsed/refractory acute myeloid leukemia (AML)- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Relapsed/refractory acute myeloid leukemia (AML) pipeline landscape is provided which includes the disease overview and Relapsed/refractory acute myeloid leukemia (AML) treatment guidelines. The assessment part of the report embraces, in depth Relapsed/refractory acute myeloid leukemia (AML) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Relapsed/refractory acute myeloid leukemia (AML) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Relapsed/refractory acute myeloid leukemia (AML) R&D. The therapies under development are focused on novel approaches to treat/improve Relapsed/refractory acute myeloid leukemia (AML).

Relapsed/refractory acute myeloid leukemia (AML) Emerging Drugs Chapters

This segment of the Relapsed/refractory acute myeloid leukemia (AML) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Relapsed/refractory acute myeloid leukemia (AML) Emerging Drugs

APG-2575: Ascentage Pharma APG-2575 is a novel oral Bcl-2 selective small molecule inhibitor under development by Ascentage Pharma. It restores the programmed cell death mechanism (apoptosis) of tumor cells by selectively inhibiting Bcl-2 protein, thereby inducing tumor cell apoptosis., to achieve the purpose of tumor treatment. APG-2575 is the first locally developed Bcl-2 selective inhibitor to enter clinical stage in China. APG-2575 has been granted orphan drug designation by the US FDA for five indications (Indications: refractory chronic lymphocytic leukemia CLL, multiple myeloma, Waldenström macroglobulinemia, acute myeloid leukemia, follicularlymphoma).

CLN 049: Cullinan Oncology CLN-049 (Florentine) is a humanized bispecific T cell engaging antibody being developed for the treatment of acute myeloid leukemia (AML). CLN-049 is designed to simultaneously bind to FLT3 on targeted leukemic cells and to CD3 on T cells, triggering the T cells to kill the selected cancer cells via their intrinsic cytolytic mechanisms. FLT3 is expressed frequently on AML cells and leukemic blasts but minimally on healthy blood cells, unlike other tumor surface antigens identified in AML, such as CD33 and CD123. CLN-049 can mediate potent and specific lysis of AML cells in vitro and promotes enhanced survival of mice bearing AML tumors. A phase I clinical trial with CLN-049 is currently ongoing for the treatment of patients with relapsed/refractory AML orMDS.

Lanraplenib: Kronos Bio Lanraplenib, is a next-generation SYK inhibitor that has previously been studied as a potential treatment for autoimmune diseases. In preclinical studies, Lanraplenib was shown to have anti-leukemic activity against NPM1-mutated and FLT3-mutated AML samples. Lanraplenib, is being developed for the treatment of patients with relapsed/refractory FLT3-mutated AML and patients newly diagnosed with NPM1-mutated and/or FLT3-mutated AML who are older than 75 years old or are not eligible for intensiveinductionchemotherapy.

Relapsed/refractory acute myeloid leukemia (AML): Therapeutic Assessment

This segment of the report provides insights about the different Relapsed/refractory acute myeloid leukemia (AML) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Relapsed/refractory acute myeloid leukemia (AML)

There are approx. 50+ key companies which are developing the therapies for Relapsed/refractory acute myeloid leukemia (AML). The companies which have their Relapsed/refractory acute myeloid leukemia (AML) drug candidates in the most advanced stage, i.e. Phase I/II include, Ascentage Pharma.

Phases

This report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Relapsed/refractory acute myeloid leukemia (AML) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Relapsed/refractory acute myeloid leukemia (AML): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Relapsed/refractory acute myeloid leukemia (AML) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Relapsed/refractory acute myeloid leukemia (AML) drugs.

Relapsed/refractory acute myeloid leukemia (AML) Report Insights

• Relapsed/refractory acute myeloid leukemia (AML) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Relapsed/refractory acute myeloid leukemia (AML) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Relapsed/refractory acute myeloid leukemia (AML) drugs?
• How many Relapsed/refractory acute myeloid leukemia (AML) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Relapsed/refractory acute myeloid leukemia (AML)?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Relapsed/refractory acute myeloid leukemia (AML) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Relapsed/refractory acute myeloid leukemia (AML) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Ascentage Pharma
• Cullinan Oncology
• Kronos Bio
• Maxinovel Pharmaceuticals
• AB Science
• CicloMed
• Karyopharm Therapeutics
• Antengene Corporation
• GlycoMimetics
• Servier
• Novartis
• ImmunoGen

Key Products

• APG-2575
• CLN 049
• Lanraplenib
• MAX-40279-01
• AB8939
• Fosciclopirox
• KPT-9274
• Uproleselan
• S65487
• IMGN632

This product will be delivered within 1-3 business days.